Press Releases

Press Releases

Press Releases

Aug 11, 2022
Larimar plans to submit a complete response to CTI-1601’s clinical hold in the third quarter of 2022 In conjunction with the complete response, Larimar is proposing a Phase 2, four-week dose exploration study in Friedreich’s ataxia (FA)   patients as CTI-1601’s next clinical trial Cash and
Displaying 1 - 10 of 38